Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TYMTRAN vs ANEXSIA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
TYMTRAN (pegvorhyaluronidase alfa) is a recombinant human hyaluronidase that degrades hyaluronic acid (HA) in the tumor microenvironment, reducing interstitial fluid pressure and improving drug penetration.
ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.
FDA-approved: Treatment of metastatic pancreatic ductal adenocarcinoma (m PDAC) in combination with nab-paclitaxel and gemcitabine
Relief of moderate to moderately severe pain
Intramuscular injection: 0.5 mg/kg body weight (maximum 25 mg per dose) administered once daily for 2 to 3 days. Oral: Not available.
50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.
Terminal elimination half-life is 12-15 hours in healthy adults, allowing twice-daily dosing; extended to 20-25 hours in hepatic impairment.
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (Cr Cl <30 m L/min).
Metabolized via proteolysis into small peptides and amino acids; not metabolized by CYP450 enzymes.
Hydrocodone is metabolized via CYP2D6 and CYP3A4 to hydromorphone and norhydrocodone. Acetaminophen is primarily metabolized via hepatic glucuronidation and sulfation; a minor pathway via CYP2E1 produces NAPQI, which is detoxified by glutathione.
Primarily hepatic metabolism via CYP3A4, with 70% excreted in feces as metabolites and 20% in urine as unchanged drug and metabolites.
Approximately 70% renal (unchanged drug and metabolites), 20% biliary/fecal, 10% other.
95% bound to albumin and alpha-1-acid glycoprotein.
Approximately 95% bound to plasma albumin and alpha-1-acid glycoprotein.
Volume of distribution is 0.6-0.8 L/kg, indicating moderate tissue binding.
0.2-0.4 L/kg, indicating limited extravascular distribution primarily confined to plasma and interstitial fluid.
Oral bioavailability is 70% with food; decreased to 50% when taken with high-fat meal.
Oral: 80-90%; Intramuscular: 90-100%; Rectal: 70-80%.
No dose adjustment required for mild to moderate renal impairment (GFR ≥30 m L/min). For severe renal impairment (GFR <30 m L/min) or end-stage renal disease, avoid use due to increased risk of myopathy.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: 50% dose reduction; GFR <15 m L/min: avoid use.
Contraindicated in Child-Pugh class C. For Child-Pugh class A or B, reduce dose by 50% and monitor creatine kinase levels.
Child-Pugh A: no adjustment; Child-Pugh B: 50% dose reduction; Child-Pugh C: avoid use.
Not recommended for children under 2 years of age. For ages 2 to 12 years, 0.5 mg/kg intramuscular injection once daily for 2 to 3 days, maximum 10 mg per dose. For ages 13 to 17 years, adult dosing applies.
1-2 mg/kg/dose orally every 6 hours; maximum 6 mg/kg/day.
No specific dose adjustment, but use with caution due to increased risk of myopathy; consider lower starting dose (0.3 mg/kg) and monitor renal function and creatine kinase levels.
Initiate at 25 mg every 6 hours; increase cautiously; monitor renal function.
None.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity from acetaminophen.
Hypersensitivity reactions including anaphylaxis,Hemolytic uremic syndrome (HUS) and thrombotic microangiopathy (TMA) reported in combination therapy,Hepatotoxicity: Monitor liver function,Neutropenia: Monitor complete blood counts
Risk of respiratory depression, especially in elderly or debilitated patients; adrenal insufficiency; severe hypotension; seizures; opioid-induced hyperalgesia; acetaminophen hepatotoxicity (avoid exceeding 4 g/day); serotonin syndrome if used with serotonergic agents.
None.
Hypersensitivity to hydrocodone or acetaminophen; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting; known or suspected GI obstruction; severe hepatic impairment; concomitant use of MAOIs or within 14 days.
Grapefruit juice may increase fentanyl serum concentrations and should be avoided during treatment. Alcohol consumption is contraindicated due to additive CNS depression and increased risk of respiratory depression. No other specific food interactions; however, patients should maintain a stable diet to avoid pharmacokinetic variability.
Avoid alcohol; may increase risk of hepatotoxicity and GI bleeding. Limit caffeine intake from coffee, tea, cola, or energy drinks due to added caffeine content. High-fat meals may delay absorption; take on empty stomach for faster onset if tolerated.
TYMTRAN (tyrosine kinase inhibitor) is contraindicated in pregnancy. Based on its mechanism of action and animal studies, it is expected to cause fetal harm. First trimester exposure is associated with increased risk of major congenital malformations, including cardiac and skeletal anomalies. Second and third trimester exposure may lead to fetal growth restriction, oligohydramnios, and potential fetal death. Women of childbearing potential must use effective contraception during treatment and for at least 2 weeks after the last dose.
First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus arteriosus and oligohydramnios due to fetal renal effects; avoid use after 30 weeks gestation.
It is unknown whether TYMTRAN is excreted in human breast milk. Due to the potential for serious adverse reactions in nursing infants, women should not breastfeed during treatment and for 2 weeks after the last dose. No M/P ratio is available.
Excreted into breast milk in low concentrations (M/P ratio not established). Not recommended during breastfeeding due to potential for adverse effects in the infant, including renal impairment and gastrointestinal bleeding.
No specific dosing adjustments have been established for TYMTRAN during pregnancy as its use is contraindicated. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, enhanced clearance) may theoretically reduce drug exposure, but dose modification is not recommended due to teratogenic risk. Treatment should be discontinued if pregnancy occurs.
Dose adjustment not generally required; however, due to increased renal clearance in pregnancy, shortened dosing intervals may be necessary for sustained efficacy. Use lowest effective dose for shortest duration.
TYMTRAN (transmucosal immediate-release fentanyl) is contraindicated in opioid-naïve patients due to risk of fatal respiratory depression. Use only for breakthrough cancer pain in patients already on ≥60 mg oral morphine/day. Do not substitute on a mcg-to-mcg basis with other fentanyl products (differing bioavailability). Monitor for signs of excessive sedation and respiratory depression. Patients must have immediate access to naloxone. Instruct patients to place the entire tablet in the buccal cavity above a molar, not to suck or chew, and avoid swallowing.
ANEXSIA is a combination analgesic containing paracetamol, ibuprofen, and caffeine. It is contraindicated in patients with active peptic ulcer disease, severe hepatic impairment, or hypersensitivity to NSAIDs. Avoid concurrent use with other NSAIDs or paracetamol-containing products. Monitor renal function in elderly or dehydrated patients. Caffeine may exacerbate anxiety or insomnia.
Take TYMTRAN only for breakthrough cancer pain as prescribed.,Do not use in short-term pain such as after surgery or for headaches.,Place the tablet in the buccal pouch above a back tooth; allow to dissolve completely.,Do not suck, chew, or swallow the tablet; this leads to lower effectiveness and risk.,If two tablets are needed, place one on each side of the mouth.,Wait at least 4 hours before treating another episode of breakthrough pain.,Store out of reach of children and away from pets; accidental use may be fatal.,Keep naloxone available and ensure family members know how to use it.,Report severe drowsiness, confusion, slow heartbeat, or trouble breathing immediately.,Do not drink grapefruit juice while taking TYMTRAN (grapefruit juice can increase fentanyl levels).,Avoid alcohol and other central nervous system depressants (e.g., sedatives, tranquilizers).,Dispose of unused tablets via a drug take-back program or by flushing down the toilet.,Do not stop suddenly or change dose without consulting prescriber.
Do not exceed recommended dose; overdosage of paracetamol can cause liver damage.,Take with food or milk to reduce gastrointestinal upset.,Avoid alcohol while taking this medication to reduce risk of liver toxicity and GI bleeding.,Discontinue use and consult if signs of allergic reaction, GI bleeding, or liver problems occur.,Caffeine may cause nervousness, insomnia, or increased heart rate; limit caffeine-containing foods and beverages.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TYMTRAN vs ANEXSIA, answered by our medical review team.
TYMTRAN is a Opioid analgesic combination that works by TYMTRAN (pegvorhyaluronidase alfa) is a recombinant human hyaluronidase that degrades hyaluronic acid (HA) in the tumor microenvironment, reducing interstitial fluid pressure and improving drug penetration.. ANEXSIA is a Opioid Analgesic Combination that works by ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TYMTRAN and ANEXSIA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TYMTRAN is: Intramuscular injection: 0.5 mg/kg body weight (maximum 25 mg per dose) administered once daily for 2 to 3 days. Oral: Not available.. The standard adult dose of ANEXSIA is: 50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TYMTRAN and ANEXSIA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TYMTRAN is classified as Category C. TYMTRAN (tyrosine kinase inhibitor) is contraindicated in pregnancy. Based on its mechanism of action and animal studies, it is expected to cause fetal harm. First trimester exposu. ANEXSIA is classified as Category C. First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.